| Literature DB >> 34955089 |
Kaige Wang1, Donghua Ren2, Zhixin Qiu1, Weimin Li1.
Abstract
BACKGROUND: Pregnancy complicated with tuberculosis is increasingly common. The clinical characteristics of pregnancy complicated with miliary tuberculosis are summarized in this study.Entities:
Keywords: ARDS; IVF-ET; Pregnancy; bone marrow tuberculosis; miliary tuberculosis
Mesh:
Year: 2022 PMID: 34955089 PMCID: PMC8725907 DOI: 10.1080/07853890.2021.2018485
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 4.709
Clinical characteristics of pregnancy complicated with military tuberculosis.
| Characteristics | All | Natural pregnancies | Pregnancies after IVF-ET | |
|---|---|---|---|---|
| Numbers | 23 | 11 | 12 | |
| Average age, years, mean (SD) | 28.39 (5.74) | 27.45 (6.73) | 29.25 (4.81) | .467 |
| Pregnancy age at symptom onset, mean (SD) | 13.96 (8.53) | 16.82 (9.38) | 11.33 (7.05) | .132 |
| Cases with symptom onset in the first trimester (≤13 weeks) | 12 (52.1) | 3 (13.0) | 9 (39.1) |
|
| Cases with symptom onset in the second trimester (13–28 weeks) | 10 (43.4) | 7 (30.4) | 3 (13.0) | .062 |
| Twin pregnancy, | 4 (17.4) | 0 | 4 (33.3) |
|
| Time from symptom onset to diagnosis, days, mean (SD) | 33.00 (27.40) | 38.45 (32.52) | 28.00 (21.99) | .373 |
| Length of stay in hospital, days, mean (SD) | 23.96 (13.78) | 25.82 (13.30) | 22.25 (14.57) | .547 |
| Initial symptoms, | ||||
| Fever | 22 (95.7) | 10 (90.9) | 12 (100.0) | .965 |
| Cough | 12 (52.2) | 6 (54.5) | 6 (50.0) | 1 |
| Dyspnoea | 16 (69.6) | 9 (81.8) | 7 (58.3) | .442 |
| Chest pain | 3 (13.0) | 2 (18.2) | 1 (8.3) | .936 |
| Headache | 4 (17.4) | 2 (18.2) | 2 (16.7) | 1 |
| Abdominal pain | 4 (17.4) | 2 (18.2) | 2 (16.7) | 1 |
| Complications, | ||||
| Tuberculous pleurisy | 3 (13.0) | 2 (18.2) | 1 (8.3) | .936 |
| Abdominal tuberculosis | 3 (13.0) | 2 (18.2) | 1 (8.3) | .936 |
| Tuberculous encephalopathy | 4 (14.7) | 2 (18.2) | 2 (16.7) | 1 |
| Bone marrow tuberculosis | 2 (8.7) | 2 (18.2) | 0 (0.0) | .421 |
| Pneumothorax | 3 (13.0) | 2 (18.2) | 1 (8.3) | .936 |
| Respiratory failure | 11 (47.8) | 6 (54.5) | 5 (41.7) | .842 |
| ARDS | 8 (34.8) | 5 (45.5) | 3 (25.0) | .555 |
| Concomitant bacterial infection | 6 (26.1) | 4 (36.4) | 2 (16.7) | .549 |
| Concomitant fungal infection | 2 (8.7) | 1 (9.1) | 1 (8.3) | 1 |
| Treatments, | ||||
| Hormone use | 11 (47.8) | 8 (72.7) | 3 (25.0) | .061 |
| Mechanical ventilation | 6 (26.1) | 4 (36.4) | 2 (16.7) | .549 |
| Anti-TB regimens | ||||
| HREZ | 13 (56.5) | NA | NA | NA |
| HL2EO | 6 (26.1) | NA | NA | NA |
| HREO | 1 (4.3) | NA | NA | NA |
| HEO | 3 (13.0) | NA | NA | NA |
| Fate, died | ||||
| Pregnant woman | 1 (4.3) | 1 (9.1) | 0 | .965 |
| Foetus | 9 (39.1) | 4 (36.4) | 5 (41.7) | .833 |
Initial laboratory analysis of pregnancy complicated with military tuberculosis.
| Initial laboratory analysis | Natural pregnancies | Pregnancies after VF-ET | ||
|---|---|---|---|---|
| Complete blood count | ||||
| White blood cell count; ×109/L; normal range 3.5–9.5 | 7.17 (5.81) | |||
| Increase | 4 (17.4) | 2 (18.2%) | 2 (16.7%) | .138 |
| Decrease | 13 (56.5) | 3 (27.3%) | 0 | .833 |
| Lymphocyte count; ×109/L; normal range > 1.1 | 0.73 (0.23) | |||
| Decreased | 21 (91.3) | 10 (90.9%) | 11 (91.7%) | .833 |
| Neutrophil count; ×109/L; normal range 1.8–6.3 | 5.41 (3.21) | |||
| Increase | 7 (30.4) | 4 (36.4%) | 3 (25.0%) | .825 |
| Red blood cell count, ×109/L; normal range 3.5–5 | 3.15 (1.30) | |||
| Decrease | 21 (91.3) | 11 (100%) | 10 (83.3%) | .366 |
| Haemoglobin; g/L; normal range > 130 | 98.70 (14.87) | |||
| Decrease | 21 (91.3) | 11 (100%) | 10 (83.3%) | .499 |
| Platelet count; ×109/L; normal range 100–300 | 195.48 (108.31) | |||
| Decrease | 4 (17.4) | 3 (27.3%) | 1 (8.3%) | .459 |
|
reactive protein; mg/L; normal range < 10 | 66.8 (35.01) | |||
| 23 (100) | 11 (100%) | 12 (100%) | NA | |
| Procalcitonin; ng/mL; normal range < 0.1 | 2.0 (4.28) | |||
| Increase | 23 (100) | 11 (100%) | 12 (100%) | NA |
| ESR; mm/h; normal range <15 | 55.04 (22.04) | |||
| Increase | 22 (95.7) | 11 (100%) | 11 (91.7%) | 1 |
| Cardial markers | ||||
| Creatine kinase-MB; ng/mL; normal range < 5 | 16.22 (14.18) | |||
| 13 (56.5) | 23 (100%) | 23 (100%) | NA | |
| Troponin; ng/mL; normal range <0.04 ng/mL | 13.33 (12.41) | |||
| 6 (26.1) | 5 (45.5%) | 1 (8.3%) | .121 | |
| Brain natriuretic peptide; pg/mL; normal range <900 | 583.78 (959.44) | |||
| 19 (82.6) | 9 (81.8%) | 10 (83.3%) | 1 | |
| Blood biochemical analysis | ||||
| Total bilirubin | 18.06 (15.58) | |||
| 2 (8.7) | 2 (18.2%) | 0 | .152 | |
| Direct bilirubin | 11.11 (14.42) | |||
| 8 (34.8) | 5 (45.5%) | 3 (25.0%) | .555 | |
| Alanine aminotransferase; U/L; normal range <50 | 61.87 (40.07) | |||
| 11 (47.8) | 3 (27.3%) | 8 (66.7%) | .141 | |
| Aspartate aminotransferase; U/L; normal range <40 | 75.48 (46.45) | |||
| 15 (65.2) | 7 (63.6%) | 8 (66.7%) | 1 | |
| Creatinine; μmol/L; normal range < 111 | 51.43 (14.34) | |||
| 1 (4.3) | 16 (31%) | 3 (12%) | NA | |
| Albumin; g/L; normal range >35 | 28.69 (4.09) | |||
| 23 (100) | 11 (100%) | 12 (100%) | NA | |
| Lactic dehydrogenase; U/L; normal range <250 | 406.04 (179.31) | |||
| 23 (100) | 11 (100%) | 12 (100%) | NA | |
| Creatine kinase; U/L; normal range <310 | 62.09 (195.81) | |||
| 9 (39.1) | 1 (9.1%) | 0 (0%) | .833 | |
| Coagulation | ||||
| Prothrombin time; sec; normal range 9–16 | 12.03 (2.05) | |||
| 6 (26.1) | 2 (18.2%) | 4 (33.3%) | .725 | |
| Activated partial prothrombin time; sec; normal range 28–44 | 34.65 (9.14) | |||
| 6 (26.1) | 2 (18.2%) | 4 (33.3%) | .725 | |
| D-Dimer; mg/L; normal range <0.55 | 3.83 (3.08) | |||
| 59 (76.6) | 11 (100%) | 12 (100%) | NA | |
| Cell immunity | ||||
| CD4+ cell count; /µL; normal range >404 | 367.61 (128.63) | |||
| 10 (43.5) | 4 (36.4%) | 6 (50.0%) | .812 | |
| CD8+ cell count, /µL; normal range >220/µL | 296.09 (116.13) | |||
| 19 (82.6) | 8 (72.7%) | 11 (91.7%) | .518 | |
| Lactic acid in blood gas analysis; mmol/L; normal range <1.5 | 1.99 (1.41) | |||
| Increase | 9 (39.1) | 5 (45.5%) | 4 (33.3%) | .867 |
| BCG skin test positive | 12 (52.2) | 6 (54.5%) | 6 (50.0%) | 1 |
| TB-IGRA positive | 15 (65.2) | 7 (63.6%) | 8 (66.7%) | 1 |
| Tuberculosis antibody positive | 9 (39.1) | 4 (36.4%) | 5 (41.7%) | 1 |
| Sputum AFB positive | 1 (4.3) | 0 | 1 (8.3%) | 1 |
| Sputum TB-DNA positive | 5 (21.7) | 3 (27.3%) | 2 (16.7%) | .912 |
| Sputum TB-bacillus culture positive | 3 (13.0) | 1 (9.1%) | 2 (16.7%) | 1 |
Figure 1.Image of chest CT scan. (A and B) Chest HRCT of a case on admission showed multiple miliary nodular lesions distributed diffusively in both lungs, partially clustered and consolidated. (C and D) Chest HRCT after 6 months treatment showed absorption of miliary nodular lesions in bilateral lung.
Figure 2.Pathological image of bone marrow biopsy. Pathological image showed necrotizing granuloma reactions in bone marrow (A and C: HE staining, 100×; B and D: HE staining, 200×), but acid-fast staining was negative.